File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Sox7—a potential tumour suppressor in myeloid malignancies

TitleSox7—a potential tumour suppressor in myeloid malignancies
Authors
Issue Date2010
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/
Citation
The 15th Medical Research Conference, Hong Kong, 16 January 2010. In Hong Kong Medical Journal, 2010, v. 16 n. 1S, p. 19 Abstract no. 22 How to Cite?
AbstractIntroduction: Sry-related HMG box (SOX) genes are a family of 20 proteins characterised by a highly conserved high-mobility-group (HMG) domain. The sox genes have been shown to regulate diverse processes during embryonic development and neoplastic transformation. However, their roles in haematopoiesis and leukaemogenesis are unclear. Methods: Bone marrow (BM) or peripheral blood samples of patients with myeloid (acute myeloid leukaemia [AML], myelodysplastic syndrome [MDS], chronic myelogenous leukaemia [CML]) and lymphoid (acute lymphoblastic leukaemia [ALL]) malignancies, as well as normal BM and umbilical cord blood (UCB), were prospectively collected. Mononuclear cells (MNC) and CD34+ cells were isolated. Expression of sox genes was evaluated by reverse-transcription polymerase chain reaction (RT-PCR) and western blotting. Methylation of CpG island in sox7 promoter was evaluated by bisulfite sequencing and methylation specific PCR. Leukaemic cell lines were treated with 5-aza-2’deoxycytidine (5-aza-dC). Results: Sox7 was expressed in normal BM MNC (5/14) and UCB CD34+ (6/6) but not in AML (n=33), CML (n=13) and MDS (n=16), as well as four AML-derived cell lines (ML-2, KG-1, NB4, K562). Sox7 was also expressed in 17/23 ALL cases and a cell line derived from precursor B-cell ALL (Nalm-20). None of the other 19 sox genes showed differential expression between normal, myeloid, and lymphoid malignancies. In silico analysis revealed CpG island within the promoter and exon 1 region of sox7 gene. There was CpG hypermethylation as showed by both bisulfite sequencing and methylation-specific PCR. Treating AML-derived cell lines (KG-1, ML-2, and K562) with 5-aza-dC re-expressed sox7 gene. Conclusion: Sox7 exhibited differential gene expression between normal haematopoietic cells and myeloid malignancies and was silenced in the latter due to promoter CpG island methylation. Its role as a tumour suppressor gene should be further evaluated.
Persistent Identifierhttp://hdl.handle.net/10722/224391
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorFan, A-
dc.date.accessioned2016-04-01T07:33:13Z-
dc.date.available2016-04-01T07:33:13Z-
dc.date.issued2010-
dc.identifier.citationThe 15th Medical Research Conference, Hong Kong, 16 January 2010. In Hong Kong Medical Journal, 2010, v. 16 n. 1S, p. 19 Abstract no. 22-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/224391-
dc.description.abstractIntroduction: Sry-related HMG box (SOX) genes are a family of 20 proteins characterised by a highly conserved high-mobility-group (HMG) domain. The sox genes have been shown to regulate diverse processes during embryonic development and neoplastic transformation. However, their roles in haematopoiesis and leukaemogenesis are unclear. Methods: Bone marrow (BM) or peripheral blood samples of patients with myeloid (acute myeloid leukaemia [AML], myelodysplastic syndrome [MDS], chronic myelogenous leukaemia [CML]) and lymphoid (acute lymphoblastic leukaemia [ALL]) malignancies, as well as normal BM and umbilical cord blood (UCB), were prospectively collected. Mononuclear cells (MNC) and CD34+ cells were isolated. Expression of sox genes was evaluated by reverse-transcription polymerase chain reaction (RT-PCR) and western blotting. Methylation of CpG island in sox7 promoter was evaluated by bisulfite sequencing and methylation specific PCR. Leukaemic cell lines were treated with 5-aza-2’deoxycytidine (5-aza-dC). Results: Sox7 was expressed in normal BM MNC (5/14) and UCB CD34+ (6/6) but not in AML (n=33), CML (n=13) and MDS (n=16), as well as four AML-derived cell lines (ML-2, KG-1, NB4, K562). Sox7 was also expressed in 17/23 ALL cases and a cell line derived from precursor B-cell ALL (Nalm-20). None of the other 19 sox genes showed differential expression between normal, myeloid, and lymphoid malignancies. In silico analysis revealed CpG island within the promoter and exon 1 region of sox7 gene. There was CpG hypermethylation as showed by both bisulfite sequencing and methylation-specific PCR. Treating AML-derived cell lines (KG-1, ML-2, and K562) with 5-aza-dC re-expressed sox7 gene. Conclusion: Sox7 exhibited differential gene expression between normal haematopoietic cells and myeloid malignancies and was silenced in the latter due to promoter CpG island methylation. Its role as a tumour suppressor gene should be further evaluated.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/-
dc.relation.ispartofHong Kong Medical Journal-
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.titleSox7—a potential tumour suppressor in myeloid malignancies-
dc.typeConference_Paper-
dc.identifier.hkuros180751-
dc.identifier.volume16-
dc.identifier.issue1S-
dc.identifier.spage19 Abstract no. 22-
dc.identifier.epage19 Abstract no. 22-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats